Xiogenix’s Post

Are you working within cell and gene therapy development? Check out the event from Technology Networks airing Nov 13th, including Ryan Nai's presentation on #plasmid and double-stranded #DNA analyses using the latest kit from #SCIEX, streamlining purity determination and size estimation. 💥 #mRNA #vaccines #SCIEX #CE #capillaryelectrophoresis

The biotech industry is evolving at rapid speed, and staying ahead demands a proactive approach. In this on-demand webinar, our CTO, Hanna P. Lesch, along with industry experts share their practical insights to help you navigate the challenges and seize opportunities in cell and gene therapy. By watching, you'll learn: 🔍 Key strategies to secure vital funding in a competitive market 🏆 How to refine your operations while maintaining top-notch quality and regulatory compliance 🌐 How to overcome hurdles to get your therapies approved and into the market 💰 Tips for mastering the complexities of pricing to ensure your therapies reach patients and remain profitable Watch on-demand below. https://lnkd.in/e7a-zrZx #GeneTherapy #CGT

New Year, BIG News! 📢 PBS Biotech secures $17 Million in Growth Capital to Accelerate Delivery of Next Generation Cell and Regenerative Therapies. We are committed to scaling up our business to meet the growing demands of the cell and gene therapy industry to bring life-saving treatments faster with the support of our investors, Avego and BroadOak Capital Partners. 📽️ DISCLAIMER: The video below is strictly for entertainment purposes and does not accurately represent mixing in the vertical-wheel bioreactor. For more questions, please feel free to contact us! 👉 Full press release available to read here: https://bit.ly/3Pq8csA

This has to be the biggest news in the Bioprocessing industry so far in 2025! Thrilled is an under statement, #verdot has market leading technology in the field of downstream bioprocessing with columns and hardware. With a focus on newer modalities like mRNA and Gene Therapy together with mAbs. We are proud to work alongside #QualiumInvestissement and #LauxeraCapitalPartners. Jacques Pancrazi, Jean-Brice Lachaux, Pierre Moustial, Alex Slack, Edoardo Fracchia, Alessandra Malaval, Charles Ruban, Brian Gerwe, Lorraine Attridge, Sebastien MAGNAUD, Sebastien Lefebvre, David LE FUR, Bradford Beatty, Chris Major

VERDOT is excited to announce the €10 million partnership with BioProcess360 Partners, marking a significant step in our journey to scale globally and drive innovation in bioprocessing. The #bioprocessing and #lifesciences industries are undergoing significant transformations. As new molecular entities like nucleic acids and gene therapies redefine the landscape, VERDOT remains committed to helping clients overcome challenges and seize opportunities. This investment brings invaluable expertise and networks to strengthen our global presence and scale our capabilities. Together with #QualiumInvestissement and #LauxeraCapitalPartners, we aim to deliver innovative solutions that reduce time to market, improve process efficiency, and support access to groundbreaking therapies. 🚀 Here’s to the next phase of growth and innovation! For further information, visit: [https://lnkd.in/ey8gtB45] #VERDOT #LifeSciences #Bioprocessing #Innovation #GrowthStrategy #Biopharma #Partnership

At #JPM2025 #JPM25? Join us tomorrow to learn more about our mission and the progress we’re making towards unlocking the potential of gene therapy for all.

“As the advanced therapy sector approaches a critical juncture in its growth, the industry’s ability to navigate these challenges will define its trajectory and potential to revolutionize treatment paradigms.” – Deloitte’s 2024 Advanced Therapy Industry Report Examining the current landscape of cell and gene therapy, with input from 376 respondents across the ecosystem, Deloitte's report identifies both challenges and opportunities across research, development, manufacturing, commercialization and patient access. Key insights from the report include: ⚙️Over 40% of industry leaders are unsure about meeting the future demand for advanced therapies ⚙️Nearly 90% of therapy developers are now collaborating with external manufacturers to accelerate the path to market ⚙️Payer and reimbursement issues remain a top concern for the commercialization of advanced therapies We’ve summarized the key takeaways ⬇️ Download the full report: https://lnkd.in/eDFPAutA #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

Don't miss Miloš Miljković, M.D. who will be joining our panel discussion on Cell & Gene Therapy Manufacturing: A Look at Supply Chains, Treatment Centers, and Patient Slots at the Cell and Gene Virtual Event on November 20. https://ow.ly/yP6y50TKZAY Since the introduction of CAR-T cell therapies like Novartis' Kymriah, production challenges have been a key focus for developers. In this session, we’ll explore the innovations in manufacturing that are addressing these challenges, from supply chain issues to capacity management, ensuring patients receive the treatments they need. Get ready for an in-depth discussion on the latest manufacturing advancements and how they're shaping the future of cell and gene therapies! Register now: https://ow.ly/yP6y50TKZAY #CellandGene #Biotech #Manufacturing #CAR-T #SupplyChain #FierceCellAndGene #HealthcareInnovation

Fascinating podcast interview with Miguel Forte, CEO of Kiji Therapeutics and President of ISCT, International Society for Cell & Gene Therapy with Matthew Pillar, host of the #BusinessOfBiotech podcast and editor of Bioprocess Online. As the publications says, 'Miguel Forte, M.D. simply can't stop finding places to apply his talents and energy to influence the advanced therapies landscape. The experiences he's amassed give him a unique perspective on the industry's path forward, how to navigate the regulatory gauntlet, the role of industry associations and alliances in a biotech's success, balancing the demands of multi-point leadership, changing the ATMP accessibility paradigm, and more. On this episode of the Business of Biotech, Dr. Forte shares generously on all of it.' Miguel contributes to a full 360 degree view on the #cellandgenetherapy #CGT sector and how to drive #commercial and #therapeutic success for patients. https://lnkd.in/exGkZnav

Eureka Biotechnology will be at this year’s ASGCT 27th Annual Meeting May 7 - 11, 2024, in Baltimore，MD. Connect with our team of experts throughout this event and learn insights into lentiviral vectors manufacturing.   Lentivirus is one of the widely used viral vectors in cell & gene therapy, and the mainstream production system is the four-plasmid transfection system which faces the challenges of high plasmids costs and batch variability at a commercial production scale. To overcome these challenges, Eureka Biotechnology has developed the EuLV Stable System, a suspension-adopted, inducible lentiviral vector production system.   The EuLV Stable System features two cutting-edge technology platforms: the Packaging Cell Line System (PCL) and the Stable Producer Cell Line System (SPCL). The PCL system utilizes a single plasmid transient transfection for lentiviral vector production, significantly reducing both plasmid production costs and process complexity. The SPCL system offers a transfection-free platform for lentiviral vector production, thereby eliminating the need for plasmid manufacture and transfection steps. This results in transduction titers that are 10 to 100 times higher compared to traditional methods.   The EuLV Stable System streamlines the CMC process and decreases manufacturing costs, presenting a promising solution to alleviate the current bottleneck in lentiviral vector manufacturing.   Learn more: https://lnkd.in/gb4GvTpB #ASGCT #Lentiviral Vector #LVV #cell therapy #gene therapy